Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

5d ago TTAB Proceedings
Favicon for changeflow.com

Eminem files extension for THE REAL SQUID SHADY

The USPTO Trademark Trial and Appeal Board granted an extension in TTAB proceeding 99119499. Marshall B. Mathers III (Eminem) filed the extension request against defendant Sydney Anderson regarding the trademark THE REAL SQUID SHADY. The extension was filed on 2025-11-12 and granted on 2026-04-05.

Routine Enforcement Intellectual Property
5d ago TTAB Proceedings
Favicon for changeflow.com

YOUNG N GIFTED YNG Trademark Extension

The USPTO Trademark Trial and Appeal Board recorded an extension filing (TTAB99181443) in a trademark opposition proceeding. Hallmark Licensing, LLC filed the extension request regarding the YOUNG N GIFTED YNG trademark against defendant Young N Gifted ent. The filing includes a change of correspondence address and was filed on December 16, 2025.

Routine Notice Intellectual Property
5d ago TTAB Proceedings
Favicon for changeflow.com

Valve Corp STRIKE Trademark Extension Request

The USPTO Trademark Trial and Appeal Board received a first 90-day extension request from Valve Corporation to oppose Trademark Application Serial No. 99184405 for the mark STRIKE filed by 28 Group Limited. The underlying trademark application was filed on December 17, 2025. This extension extends the deadline by which Valve must file a formal Notice of Opposition.

Routine Notice Intellectual Property
5d ago TTAB Proceedings
Favicon for changeflow.com

Trademark Opposition Extension - O Mark

The USPTO Trademark Trial and Appeal Board received a 60-day extension request from The Ohio State University to oppose Onus Health LLC's trademark application for the mark 'O'. The original opposition deadline was set for December 2025. TTAB case number 99218186.

Routine Notice Intellectual Property
5d ago TTAB Proceedings
Favicon for changeflow.com

Patek Philippe Requests 90-Day Extension to Oppose THE TWENTYFOUR SIX Mark

The USPTO Trademark Trial and Appeal Board granted Patek Philippe SA Geneve's first 90-day request to extend the time to oppose trademark application THE TWENTYFOUR SIX. The extension was granted on April 5, 2026, for TTAB case TTAB79416218, originally filed December 4, 2025. This is a routine procedural extension in a trademark opposition proceeding.

Routine Notice Intellectual Property
Favicon for www.oregon.gov

Mediation Program Surpasses $6M in Settlements

The Oregon Bureau of Labor and Industries (BOLI) announced that its Mediation Program has surpassed $6 million in settlements between Oregon workers and employers. The milestone comes as the expanded mediation model continues to move forward, providing an alternative dispute resolution pathway for employment-related conflicts in the state.

Routine Notice Employment & Labor
Favicon for www.regulations.gov

Proposed Removal of Prescriptive Rule on Indirect Vehicle Loan Servicing

The NCUA Board published a proposed rule to remove prescriptive regulatory requirements governing third-party servicing of indirect vehicle loans currently codified at §§ 701.21(h) and 741.203(c). The existing rule limits indirect loans and participations purchased from any one servicer to 50% of a credit union's net worth (increasing to 100% after 30 months of experience). The proposal seeks comment on reducing regulatory burden and providing credit unions greater operational flexibility through a principles-based supervisory approach.

Priority review Consultation Banking
Favicon for www.fda.gov

Generic Omeprazole Oral Paste Approved for Horse Gastric Ulcers

The FDA approved Gastrobim (omeprazole) oral paste as a generic equivalent to Gastrogard for the treatment and prevention of gastric ulcers in horses and foals four weeks of age and older. Sponsored by Bimeda Animal Health Ltd. of Ireland, the drug was determined bioequivalent to the brand-name product approved in 1999. Gastrobim is available only by prescription from a licensed veterinarian.

Routine Notice Pharmaceuticals
5d ago ClinicalTrials.gov
Favicon for clinicaltrials.gov

PROSECCO Trial: Cemiplimab Combination for Melanoma

ClinicalTrials.gov registered a new Phase III trial (NCT07511036) called PROSECCO, studying cemiplimab in combination therapy for melanoma. The trial is sponsored by Regeneron Pharmaceuticals and is currently listed as not recruiting. Cemiplimab is a PD-1 inhibitor marketed as Libtayo.

Routine Notice Healthcare
5d ago ClinicalTrials.gov
Favicon for clinicaltrials.gov

Clinical trial page for NCT07511049

Clinical trial page for NCT07511049

Routine Notice

Showing 7021–7030 of 46,038 changes

1 701 702 703 704 705 4604

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.